Emma Dooks
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
- Inflammatory Bowel Disease
Papers in
-
- COVID-19 Clinical Research Studies 11
- SARS-CoV-2 and COVID-19 Research 2
- Genetics 10
- Genetic Associations and Epidemiology 7
- Inflammatory Bowel Disease 3
Emma Dooks
22 papers receiving 2.7k citations
Emma Dooks's Hit Papers
Peers
Comparison fields: 5 of 97
- Infectious Diseases 1.8k
- Genetics 592
- Applied Microbiology and Biotechnology 35
- Internal Medicine 28
- Immunology 134
Countries citing papers authored by Emma Dooks
This map shows the geographic impact of Emma Dooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Dooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Dooks more than expected).
Fields of papers citing papers by Emma Dooks
This network shows the impact of papers produced by Emma Dooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Dooks. The network helps show where Emma Dooks may publish in the future.
Co-authors
The 2 scholars most cited alongside Emma Dooks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 9 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 10 | 2023 | 60 | |
| 11 | 2022 | 32 | |
| 12 | 2021 | 31 | |
| 13 | 2021 | 26 | |
| 14 | 2023 | 25 | |
| 15 | 2024 | 24 | |
| 16 | 2024 | 13 | |
| 17 | 2022 | 11 | |
| 18 | 2024 | 8 | |
| 19 | 2025 | 5 | |
| 20 | 2020 | 4 |
About Emma Dooks
Emma Dooks is a scholar working on Infectious Diseases, Genetics, Obstetrics and Gynecology, Oncology and Pulmonary and Respiratory Medicine, having authored 23 papers that have together received 2.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (11 papers), Genetic Associations and Epidemiology (7 papers), Inflammatory Bowel Disease (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Kawasaki Disease and Coronary Complications (1 paper), Pregnancy and preeclampsia studies (1 paper), COVID-19 and healthcare impacts (1 paper) and Breastfeeding Practices and Influences (1 paper). The work is most often cited by research in Infectious Diseases (1.8k citations), Genetics (592 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (28 citations) and Immunology (134 citations). Emma Dooks has collaborated with scholars based in United Kingdom, Vietnam and Switzerland. Frequent co-authors include Tomasina Stacey and David Owens. Their work appears in journals such as The Lancet, Nature, EClinicalMedicine, Human Genetics and Genomics Advances and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.